Semaglutide Does Not Slow Alzheimer Disease Progression: Phase 3 Results
Two large Phase 3 clinical trials of the GLP-1 receptor agonist semaglutide showed that two years of treatment did not slow disease progression in patients with early-stage Alzheimer disease.
Beyin bilimi laboratuvari
Observational Studies Had Raised Hope
Previous observational studies had suggested that GLP-1 receptor agonists, widely used in diabetes treatment, might slow cognitive decline and reduce dementia incidence. These findings raised exciting hypotheses that needed validation through controlled clinical trials.
EVOKE and EVOKE+ Trials
In two randomized controlled trials (EVOKE and EVOKE+) conducted in individuals with amyloid-confirmed early-stage Alzheimer disease, patients treated with oral semaglutide 14 mg were followed for two years. Results showed that semaglutide-treated patients had similar rates of clinical progression compared to the placebo group.
Vascular Risk Factor Management Still Important
Despite these results, the management of diabetes and other vascular risk factors in Alzheimer patients is still recommended. Blood sugar control, hypertension treatment, and cardiovascular health remain critical for cognitive well-being.
Source: UpToDate - Whats New in Neurology